MLICM
PNT

Metropolitan Life Insurance Company (MetLife)’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,920
Closed -$39.5K – 2406
2023
Q3 		$39.5K Buy
5,920
+915
+18% +$7.61K ﹤0.01% 1535
2023
Q2 		$45.3K Buy
5,005
+424
+9% +$3.74K ﹤0.01% 1482
2023
Q1 		$33.3K Sell
4,581
-890
-16% -$6.6K ﹤0.01% 1615
2022
Q4 		$39.9K Buy
5,471
+720
+15% +$5.34K ﹤0.01% 1609
2022
Q3 		$36.7K Hold
4,751
– – ﹤0.01% 1666
2022
Q2 		$32.4K Buy
+4,751
New +$36.4K ﹤0.01% 1773

Other funds holding PNT

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s PNT Position: Q4 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 5,920 shares — an estimated $39.5K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in PNT in Q2 2022 and held it in 6 quarters. The position peaked at $45.3K in Q2 2023. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 5,920 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $39.5K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in POINT Biopharma Global Inc. Common Stock in Q2 2022 and held it in 6 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s POINT Biopharma Global Inc. Common Stock position peaked at $45.3K in Q2 2023.
  • 1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2023, filed 14 Feb 2024.